tbuckley/cabot-search huggingface dataset:
원저 : 최근 15 년간의 B 형 간염 표면항원 및 항체 양성률 변화에 관한 연구
Authors: 이수정(Soo Jung Lee), 나호영(Ho Young Na), 박민호(Min Ho Park), 박근수(Geun Soo Park), 최성규(Sung Kyu Choi), 이강진(Kang Jin Lee), 문재동(Jai Dong Meon), 김세종(Sei Jong Kim)
Journal: Clinical and Molecular Hepatology (2001)

Background/Aims: The HBsAg positivity in the normal Korean population has been reported as 2-10Zo. It has been decreasing since hepatitis B vaccine was introduced to routine vaccination regimens in 1992. Reports on the changes of anti-HBs over the years are hard to find since the discrepancies in sensitivities of test methods used by different researchers did not allow equivalent comparisons. The purpose of this study was to evaluate the changes of HBsAg and anti-HBs posivities for a recent 15 year period. Methods: From 1998 to 2000, 4771 subjects in Chonnam province were included in this study. Serum HBsAg and anti-HBs were detected by reversed passive hemagglutination (BPHA) and passive hemagglutination (PHA) respectively. The changes in the HBsAg and anti-HBs positivity by the same test methods for the period were analyzed by comparing our results with those of 12 other previous reports. Results: The positivities of HBsAg and anti-HBs were 5.3Zo and 47.Wo. The positivity of HBsAg was significantly higher in males, while that of anti-HBs was significantly lower in males (p 40) was significantly higher statistically (p<0.01). The positivity of HBsAg decreased with years (r=-0,845, p<0.01), while that of anti-HBs increased with years (r=0.616, p<0.05). Conclusion- The positivity of HBsAg has significantly decreased and that of anti-HBs has increased with years for the period under study. (Korean J Hepatol 2001;7:299-307)
Disease-specific hashtags for online communication about cancer care.
Authors: Matthew S. Katz, Audun Utengen, Patricia F Anderson, Michael A. Thompson, Michael Fisch, Claire Johnston, Deanna J. Attai, Lee Aase, Robert Stephen Miller, Thomas Lee, Don S. Dizon
Journal: Journal of Clinical Oncology (2015)

6520 Background: A majority of patients and health care professionals are now online. Our hypothesis is that disease-specific cancer hashtags may be a way to access accurate health information and positive interactions. Methods: Based upon two de novo hashtags, #bcsm and #btsm, an organized system of hashtags, the cancer tag ontology (CTO) was designed in July 2013 for online use. We conducted a retrospective study of 25 hashtags used on Twitter April 2011 – September 2014 using data from Symplur, LLC. We classified up to 100 most active users of each hashtag as follows: patient; doctor; non-doctor health care professional (HCP); individual NOS (I); healthcare organization (HCO), other organization (OO); or spam. Tweet activity was analyzed quarterly for all tags. Results: During the study period, there were a total of 531,765 tweets from 77,454 users. The two original hashtags #bcsm and #btsm had the most use with 249,312 and 110,465 tweets, respectively. The other tags were used almost exclusively starting Q3 2013 onward. Overall, the most active new tags were those with organized Twitter-based chats: #ayacsm; #gyncsm; #lcsm; #mmsm; and #pancsm. These seven accounted for 93% of total Twitter activity. In the cohort, 11% were patients, 20% doctors, 3% HCP, 32% I, 30% HCO, 1% OO, and 3% spam. The most active top users were patients with an median of 46 tweets. Activity increased from 13,778 tweets in Q3 2011 to 75,960 tweets in Q3 2014. For the 23 structured tags, quarterly use increased from 18,098 tweets in Q3 2013 to 39,761 tweets in Q3 2014. Conclusions: We have demonstrated the feasibility and growth of organized, cancer-specific hashtags on Twitter used by a variety of stakeholders in cancer care. Use of the CTO indicates potential value of online interaction. Further study is needed to determine whether the CTO has any impact on access, outcomes or as a model for other areas of medicine.
The Role of CMV Serostatus of the Donor in the Graft Lymphoid Composition and Prediction of Gvhd and CMV Reactivation
Authors: Anna Kreutzman, Itxaso Portero Sainz, Valle Gomez Garcia De Soria, Carlos Fernandez, Royg Mercedes, Ana Marcos, Beatriz Colom Fernandez, Ana Ramirez, Laura Cardeñoso, Rafael De La Camara, Cecilia Muñoz Calleja
Journal: Blood (2014)
Examination of Blood for Tumor Cells&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Sandberg, Avery A., Moore, George E.
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article Examination of Blood for Tumor Cells Get access Avery A. Sandberg, Avery A. Sandberg Departments of Medicine and Surgery, Roswell Park Memorial Institute, Buffalo, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar George E. Moore George E. Moore Departments of Medicine and Surgery, Roswell Park Memorial Institute, Buffalo, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 19, Issue 1, July 1957, Pages 1–11, https://doi.org/10.1093/jnci/19.1.1 Published: 01 July 1957 Article history Received: 19 February 1957 Published: 01 July 1957
PSYCHIATRY AND SENSATIONALISM.
Authors: M Phillips
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Benzo[&lt;italic&gt;a&lt;/italic&gt;]pyrene Content of Certain Pyrogenic Materials
Authors: Masanori Kuratsune
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article Benzo[a]pyrene Content of Certain Pyrogenic Materials Get access Masanori Kuratsune Masanori Kuratsune Department of Hygiene, Faculty of Medicine, Kyushu University4, Fukuoka, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 6, June 1956, Pages 1485–1496, https://doi.org/10.1093/jnci/16.6.1485 Published: 01 June 1956 Article history Received: 06 December 1955 Published: 01 June 1956
Feasibility of lung clearance index in a clinical setting in pre-school children
Authors: Barrett Downing, Samantha Irving, Yvonne Bingham, Louise Fleming, Andrew Bush, Sejal Saglani
Journal: European Respiratory Journal (2016)

Lung function testing in pre-school children in the clinical setting is challenging. Most cannot perform spirometry and many infant lung function tests require sedation. Lung clearance index (LCI) derived from the multiple-breath washout (MBW) test has been shown to be sensitive to early disease changes but may be time consuming and so a shortened test (LCI 0.5 ) may be more feasible in young children. We sought to establish feasibility of MBW in unsedated pre-school children in a clinic setting and hypothesised use of LCI 0.5 would increase success rates. 116 pre-school children (28 healthy controls and 88 with respiratory disease), median age 4.0 years (range 2–6 years), underwent MBW tests unsedated in a clinic setting, using sulfur hexafluoride as a tracer gas and an adapted photoacoustic gas analyser. 81 (70%) out of 116 children completed LCI and 72% completed LCI 0.5 measurement. Test success increased significantly in patients over 3 years (0% at &lt;2.5 years, 33% at 2.5–3 years and 70% at &gt;3 years, p&lt;0.0001). LCI was elevated in those with respiratory disease compared with healthy controls. MBW is feasible in a clinic setting in unsedated pre-schoolers, particularly in those &gt;3 years old, and LCI is raised in those with respiratory disease. Use of LCI 0.5 did not increase success rate in pre-schoolers.
Observations on the Cultivation of Surgical Specimens of Human Ovaries &lt;italic&gt;in vitro&lt;/italic&gt;&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: G. G. Rose, F. M. Townsend, C. M. Pomerat
Journal: JNCI Journal of the National Cancer Institute (1951)

Observations on the Cultivation of Surgical Specimens of Human Ovaries in vitro Get access G. G. Rose, G. G. Rose Search for other works by this author on: Oxford Academic PubMed Google Scholar F. M. Townsend, F. M. Townsend Search for other works by this author on: Oxford Academic PubMed Google Scholar C. M. Pomerat C. M. Pomerat Tissue Culture Laboratory and the Department of Pathology, Medical Branch, University of Texas, Galveston, Tex. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 6, June 1951, Pages 1223–1257, https://doi.org/10.1093/jnci/11.6.1223 Published: 01 June 1951 Article history Received: 16 February 1951 Published: 01 June 1951
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
Authors: Nick Pavlakis, Katrin M. Sjoquist, Andrew J. Martin, Eric Tsobanis, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Thierry Alcindor, Christopher J. O’Callaghan, Margot J. Burnell, Niall C. Tebbutt, Sun Young Rha, Jeeyun Lee, Jae-Yong Cho, Lara R. Lipton, Mark Wong, Andrew Strickland, Jin Won Kim, John R. Zalcberg, John Simes, David Goldstein
Journal: Journal of Clinical Oncology (2016)

Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods We conducted an international (Australia and New Zealand, South Korea, and Canada) randomized phase II trial in which patients were randomly assigned at a two-to-one ratio and stratified by lines of prior chemotherapy for advanced disease (one v two) and region. Eligible patients received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred. The primary end point was progression-free survival (PFS). Final analysis included data to December 31, 2014. Results A total of 152 patients were randomly assigned from November 7, 2012, to February 25, 2014, yielding 147 evaluable patients (regorafenib, n = 97; placebo, n = 50). Baseline characteristics were balanced. Median PFS significantly differed between groups (regorafenib, 2.6 months; 95% CI, 1.8 to 3.1 and placebo, 0.9 months; 95% CI, 0.9 to 0.9; hazard ratio [HR], 0.40; 95% CI, 0.28 to 0.59; P &lt; .001). The effect was greater in South Korea than in Australia, New Zealand, and Canada combined (HR, 0.12 v 0.61; interaction P &lt; .001) but consistent across age, neutrophil-to-lymphocyte ratio, primary site, lines of chemotherapy, peritoneal metastasis presence, number of metastatic sites, and plasma vascular endothelial growth factor A. A survival trend in favor of regorafenib was seen (median, 5.8 months; 95% CI, 4.4 to 6.8 v 4.5 months; 95% CI, 3.4 to 5.2; HR, 0.74; P = .147). Twenty-nine patients assigned to placebo received open-label regorafenib after disease progression. Regorafenib toxicity was similar to that previously reported. Conclusion In this phase II trial, regorafenib was effective in prolonging PFS in refractory advanced gastric adenocarcinoma. Regional differences were found, but regorafenib was effective in both regional groups. A phase III trial is planned.
Early Phase 99Tc-HMDP Scintigraphy for the Diagnosis and Typing of Cardiac Amyloidosis
Authors: Arnault Galat, Axel Van der Gucht, Aziz Guellich, Diane Bodez, Anne-Ségolène Cottereau, Soulef Guendouz, Luc Hittinger, Jean-Luc Dubois-Randé, Violaine Plante-Bordeneuve, Emmanuel Itti, Michel Meignan, Thibaud Damy, Jean Rosso
Journal: JACC. Cardiovascular imaging (2016)
KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1).
Authors: Julie R. Brahmer, Edward S. Kim, Jin Zhang, Margaret Marie Smith, Reshma A. Rangwala, Mary E.R. O'Brien
Journal: Journal of Clinical Oncology (2015)

TPS8103 Background: The current standard-of-care first-line therapy for patients with advanced NSCLC who lack EGFR sensitizing mutations or an ALK translocation is platinum-based combination chemotherapy with or without maintenance therapy. Median OS with platinum-based chemotherapy ranges from 10-12 months. Pembrolizumab, a humanized monoclonal antibody against PD-1, has shown antitumor activity as first-line therapy for NSCLC, particularly in patients whose tumors strongly express PD-L1. Methods: In the international, open-label, phase III KEYNOTE-024 trial (NCT02142738), adults with previously untreated, advanced NSCLC without EGFR sensitizing mutations or ALK translocation that expresses PD-L1 in ≥ 50% of tumor cells are randomized 1:1 to receive a 200-mg fixed dose of pembrolizumab intravenously every 3 weeks or investigator's choice platinum-based combination chemotherapy (carboplatin or cisplatin with pemetrexed or gemcitabine or carboplatin with paclitaxel). Patients with nonsquamous NSCLC may receive pemetrexed maintenance therapy. PD-L1 expression is determined by immunohistochemistry at a central laboratory. Randomization is stratified by ECOG PS (0 vs 1), histology (squamous vs nonsquamous), and region (Asia vs rest of world). Pembrolizumab will be given for up to 35 cycles or until disease progression, intolerable toxicity, consent withdrawal, or discontinuation for other reason. Pembrolizumab recipients who experience disease progression after completing 35 cycles or who stop treatment after achieving complete response may be eligible for 1 year of pembrolizumab retreatment. Patients assigned to chemotherapy who experience progression may cross over to receive pembrolizumab. Tumor response is assessed every 9 weeks by RECIST 1.1 per central review. AEs will be monitored throughout the study and graded according to NCI CTCAE v4.0. Primary end point is PFS per RECIST 1.1 by central review. Secondary end points are ORR, OS, and safety. Enrollment is ongoing and will continue until approximately 300 patients are enrolled. Clinical trial information: NCT02142738.
Gold nanoparticle-DNA aptamer conjugate-assisted delivery of antimicrobial peptide effectively eliminates intracellular Salmonella enterica serovar Typhimurium
Authors: Ji-Hyun Yeom, Boeun Lee, Daeyoung Kim, Jong-kook Lee, Suk Kim, Jeehyeon Bae, Yoonkyung Park, Kangseok Lee
Journal: Biomaterials (2016)
Surveillance des infections humaines à Campylobacter en France -Partie 2 - Mise en place d'une surveillance nationale
Authors: A Gallay, F Simon, F. Mégraud
Journal: Eurosurveillance (2003)

En 2001, un an apres l'etude menee aupres des laboratoires montrant la faisabilite d'une surveillance de Campylobacter, 1389 laboratoires d'analyses medicales ont ete interroges sur leur volonte de participer a une surveillance. La forte proportion de reponses favorables (661, 48%) a permis la mise en place, le 1er avril 2002, d'une surveillance des infections humaines a Campylobacter.
Soundings: Holiday doppelganger
Authors: Kevin Barraclough
Journal: BMJ (2001)

From the verandah of this Landmark Trust cottage, I can see across the north Devon bay to the white Saunton Sands Hotel, maybe 20 miles distant. The sea is an uncharacteristic blue. The fractal coastline and the faded patchwork quilt of the far peninsula look like something out of a textbook on painting watercolours.

I have attended several pleasant residential courses at Saunton Sands Hotel. But it is rather odd sitting here, looking through binoculars at the hotel's shimmering, 1930s, Hercule Poirot exterior. It is, I think, the juxtaposition of the working visits on the far side of the bay—national service frameworks, revalidation—with the complete holiday tranquillity of this verandah.

The cottage in which we are staying is actually more like a wooden cricket pavilion with extraordinary views. Ninety years ago it was a summer house, set in the grounds of a palatial seaside residence, surrounded by tennis courts, lawns, and elaborately landscaped gardens. But now, nearly a century later, the ruins of the great house are deserted. They lie hidden beneath a dense, luxuriant undergrowth, while this isolated wooden bungalow is all that remains—surrounded by wild flowers, butterflies, and a steep, overgrown path down to the pebble beach. The summer afternoons of the leisured rich, who drifted their hours away in this pavilion, are now all forgotten, and the young men and women who played on the vanished tennis courts are long dead. But such is the atmosphere of the place that their ghosts are almost visible, hiding beneath the trees, in the sunlit scintillation spectra at the edge of vision.

The wonderful thing about holidays, good holidays, is that they shock you out of the familiar. That suited general practitioner in the bar at Saunton Sands Hotel, a doppelganger of myself, who pretended he wasn't bored senseless by national service frameworks, is as distant as if viewed down the wrong end of my binoculars. He moves slowly across the whitewashed vistas of the distant hotel, like a blind man, unaware that the true reality lies across the bay, in the faint echoes of privilege, boredom, and mortality, buried beneath the bracken on this steep hillside.

And then the British weather breaks and I run to get the deckchairs out of the shower of rain, and try to mediate the children's squabble.
Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease
Authors: David Goldberg, Benjamin French, Craig Newcomb, Qing Liu, Gurvaneet Sahota, Anna E. Wallace, Kimberly A. Forde, James D. Lewis, Scott D. Halpern
Journal: Clinical Gastroenterology and Hepatology (2016)
Alzheimer Therapy: Photoactive g-C<sub>3</sub>N<sub>4</sub>Nanosheets for Light-Induced Suppression of Alzheimer's β-Amyloid Aggregation and Toxicity (Adv. Healthcare Mater. 13/2016)
Authors: You Jung Chung, Byung Il Lee, Jong Wan Ko, Chan Beum Park
Journal: Advanced Healthcare Materials (2016)

The accumulation of β-amyloid peptides and their aggregation in brain is a hallmark of Alzheimer's disease. On page 1560 C. B. Park and co-workers describe a strong suppression effect of graphitic carbon nitride (g-C3N4) toward β-amyloid aggregation under light-illumination. Photoexcited g-C3N4 generates reactive oxygen species and blocks further β-amyloid aggregation by impacting conformational structure of β-amyloid, rendering it a promising material for Alzheimer therapy.
Re: Alison J. Price, Ruth C. Travis, Paul N. Appleby, et al. Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. Eur Urol 2016;70:941–51
Authors: Xu Chang, Zhang Chao, Gao Zheng-Yan
Journal: European Urology (2016)
Myocardial Ischemia
Authors: L. David Hillis, Eugene Braunwald
Journal: New England Journal of Medicine (1977)

Pharmacologic InterventionsA number of pharmacologic agents reduce myocardial ischemic injury in the laboratory animal, and some have been used in limited numbers of patients. The activation of the complement system via its alternate pathway, a shift that characterizes ischemic tissue, releases leukotactic factors and increases capillary permeability, leading to interstitial edema. As a result, the microvasculature is compressed, further diminishing blood flow to the ischemic area.18, 233 , 234 Cobra-venom factor, a protein that enzymatically cleaves C3 and prevents the effects of the complement system, reduces myocardial injury.196,197 Similarly, the kallikrein system enhances leukotactic activity, capillary permeability, interstitial edema and proteolytic activity. . . .
Effect of melanoma on immune function in regional lymph nodes (LN)
Authors: B. P. Negin, D. Panka, W. Wang, N. Tawa, J. Mullen, S. Tahan, L. Mandato, A. Polivy, J. Mier, M. Atkins
Journal: Journal of Clinical Oncology (2006)

8000 Background: Metastatic melanoma is associated with various measures of systemic and local immune suppression. We hypothesized that immune suppression in the regional LN basin exists and may facilitate melanoma progression. Methods: We collected portions of regional LNs from tumor uninvolved sentinel LNs (USLN) (remote from primary melanoma removal) and from macroscopically involved nodes (TILN) from therapeutic node dissections in successive melanoma patients. Lymphocytes were extracted, stained using surface and internal antibodies to T cell receptor zeta chain (TCRζ), T regulatory cells (CD4+CD25+ Fox 3p+) (Tregs) and tumor associated myeloid cells (CD11b+ CD14- CD15+) (TAMC), and analyzed via flow cytometer. Results from USLN specimens were compared with TILN. Results: 30 LNs (14 USLN/16 TILN) from 30 patients were evaluated. Median age of patients was 48 years (range 30–83); 20 were male. USLN patients were stage IB (12) or IIA (2); TILN patients were stage IIIB (5), IIIC (5), and IV (6). 7 patients with TILN and none with USLN have progressed. TILN had significantly less TCRζ chain expression than SLN (62% vs. 85%; p = 0.0001). This amounts to a localized decrease of 23% of TCRζ expression (95% CI 13%; 34%). No significant relationship between lymph node involvement and Treg or TAMC was documented. Conclusion: Regional LN involvement with melanoma is associated with a significant reduction in lymphocyte TCRζ expression indicating immune suppression. The mechanism for this is uncertain, but does not appear to be related to changes in Tregs or TAMC (arginase producing cells). We plan to further investigate TCRζ expression in microscopically involved SLNs and SLNs removed at time of primary excision to see if immune changes precede macroscopic tumor involvement. Supported by Harvard Skin SPORE Project 5 and Immune Monitoring Core P50CA93683–01 No significant financial relationships to disclose.
PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy
Authors: Sarah A Meadows, Huong (Marie) Nguyen, Christophe Queva, Brian J. Lannutti, Adam Kashishian, Susie Jun, Steven E. Coutre, Roger Dansey, Jason Gotlib
Journal: Blood (2013)